Lakefront Biotherapeutics (LKFT) Change in Receivables (2015 - 2020)

Lakefront Biotherapeutics (LKFT) has reported Change in Receivables for 5 consecutive years, with -$51.4 million the latest figure, recorded in Q2 2020.

• In Q2 2020, Change in Receivables fell 233.93% year-over-year to -$51.4 million; the TTM figure through Jun 2020 stood at $16.8 million (down 49.56% YoY), while the FY2025 annual figure was $100.8 million, up 403.73% from the prior year.
• Change in Receivables declined to -$51.4 million in Q2 2020 per LKFT's latest filing, from $30.4 million in the prior quarter.
• Across five years, Change in Receivables topped out at $2.6 billion in Q3 2017 and bottomed at -$2.5 billion in Q2 2017.
• Historically, Change in Receivables has averaged $11.9 million across 5 years, with a median of -$5.7 million in 2016.
• Annual changes were most pronounced in 2017 — Change in Receivables slumped 44027.92% — and 2019, when it jumped 2626.81%.
• Lakefront Biotherapeutics' Change in Receivables stood at -$5.6 million in 2016, then sank by 144.8% to -$13.6 million in 2017, then surged by 128.39% to $3.9 million in 2018, then surged by 2626.81% to $105.6 million in 2019, then sank by 148.64% to -$51.4 million in 2020.
• Business Quant data shows LKFT's Change in Receivables at -$51.4 million in Q2 2020, $30.4 million in Q1 2020, and $105.6 million in Q4 2019.